4月14日 - ** 辉瑞公司PFE.N周一称已停止开发试验性减肥药丹利普隆（danuglipron） (link)，诺和诺德NOVOb.CO股价上涨约4%。
** 一名试验患者出现了由药物引起的潜在肝损伤，但在停药后症状得到缓解。
** Nordnet 分析师 Per Hansen 将股价上涨归因于辉瑞公司的声明，并表示减肥市场和数据可以在早期阶段推动股价。
** 汉森还指出："辉瑞放弃一个项目表明，诺和诺德、礼来或新的竞争对手开展的项目并非都能取得成功。
** 如果涨势保持，诺和诺德将迎来自2月21日以来的最佳交易日
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.